Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-09-12
2011-11-08
Aeder, Sean (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
08053198
ABSTRACT:
The present invention relates to methods of diagnosing cancerous conditions in a patient, as well as methods of monitoring the progression of a cancerous condition and/or methods of monitoring a treatment protocol of a therapeutic agent or a chemotherapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
REFERENCES:
patent: 4168146 (1979-09-01), Grubb et al.
patent: 4235601 (1980-11-01), Deutsch et al.
patent: 4366241 (1982-12-01), Tom et al.
patent: 4442204 (1984-04-01), Greenquist et al.
patent: 5208535 (1993-05-01), Nakayama et al.
patent: 5807522 (1998-09-01), Brown et al.
patent: 6110426 (2000-08-01), Shalon et al.
patent: 2003/0113713 (2003-06-01), Glezer et al.
patent: 2003/0207290 (2003-11-01), Kenten et al.
patent: 2004/0022677 (2004-02-01), Wohlstadter et al.
patent: 2004/0189311 (2004-09-01), Glezer et al.
patent: 2005/0052646 (2005-03-01), Wohlstadter et al.
patent: 2005/0142033 (2005-06-01), Glezer et al.
patent: 2006/0205012 (2006-09-01), Debad et al.
patent: WO 99/26067 (1999-05-01), None
patent: WO 2004/058055 (2004-07-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Swidzinska et al (Pneumonol Alegol Pol, 2004, 72(9-10): abstract).
Tas et al (Melanoma Research, 2006, 16(5): abstract.
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Yokoyama et al (Gynecologic Oncology, 2000, 77:413-418).
Kumar et al (Anticancer Research, 2002, 22(3): 1877-1880).
Yokoe et al (Breast Cancer, 2000, 7(3): abstract).
Benoy et al (Clin Breast Cancer, 2002, 2(4):abstract).
Benoy et al (Clin Breast Cancer, 2002, 2(4):311-315).
Climente et al (Clin Transl Oncol., Jun. 2006, 8(6): Abstract).
Chen et al (Gynecologic Oncology, 2004, 630-635).
Zhao et al (Cancer Research, 2009, 69(19): 7696-7703).
Aref S. et al., “Soluble VEGF/sFLt1 Ratio is an Independent Predictor of AML Patient Out Come”,Hematology10 (2):131-134 (2005).
Aung PP et al., “Systematic Search for Gastric Cancer-Specific Genes Based on SAGE Data: Melanoma Inhibitory Activity and Matrix Metalloproteinase-10 are Novel Prognostic Factors in Patients with Gastric Cancer”,Oncogen25:2546-2557 (2006).
Bando H. et al., “Association Between Intratumoral Free and Total VEGF, Soluble VEGFR-1, VEGFR-2 and Prognosis in Breast Cancer”,British Journal of Cancer92:553-561 (2005).
Baron A.T. et al., “Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer”,Cancer Epidemiology Biomarkers Prevention14(2):306-318 (2005).
Buller R.E. et al., “CA 125 Kinetics: A Cost-Effective Clinical Tool to Evaluate Clinical Trial Outcomes in the 1990s”,American Journal of Obstetrics and Gynecology 174:1241-1254 (1996).
Buys S.S. et al., “Ovarian Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the Initial Screen of Randomized Trial”,American Journal of Obstetrics and Gynecology193:1630-1639 (2005).
Caine G.J. et al., “Changes in Plasma Vascular Endothelial Growth Factor, Angiopoietins, and Their Receptors Following Surgery for Breast Cancer”,Cancer Letters248:131-136 (2007).
Chen H. et al., “VEGF, VEGFRs Expressions and Activated STATs in Ovarian Epithelial Carcinoma”,Gynecologic Oncology94(3):630-635 (2004).
Cooper B.C. et al., “Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer”,Obstetrics&Gynecology100(1):59-64 (2002).
Dales JP et al., “Prediction of Metastasis Risk (11 Year Follow-Up) Using VEGF-RI, VEGF-R2, Tie-2/Tek and CD105 Expression in Breast Cancer (n=905)”,British Journal of Cancer90(6):1216-1221 (2004).
Debad J.D. et al., “Clinical and Biological Applications of ECL”,Electrogenerated Chemiluminescencepp. 359-396 (2004).
Enjoji M. et al., “Clinical Significance of Serum Levels of Vascular Endothelial Growth Factor and its Receptor in Biliary Disease and Carcinoma”,World Journal of Gastroenterology11(8):1167-1171 (2005).
Gill J.H. et al., “MMP-10 is Overexpressed, Proteolytically Active, and a Potential Target for Therapeutic Intervention in Human Lung Carcinomas”,Neoplasia6(6):777-785 (2004).
Gorelik E. et al., “Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer”,Cancer Epidemiology, Biomarkers&Prevention14(4):981-987 (2005).
Guidi A.J. et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Endometrial Carcinoma”,Cancer78(3):454-460 (1996).
Hoar F.J. et al., “Circulating Levels of VEGF-A, VEGF-D and Soluble VEGF-A Receptor (sFlt-1) in Human Breast Cancer”,The International Journal of Biological Markers19(3):229-235 (2004).
Hellstrom I. et al., “Mesothelin Variant 1 is Released from Tumor Cells as a Diagnostic Marker”,Cancer Epidemiology, Biomarkers&Prevention15(5):1014-1020 (2006).
Hsieh F-C et al., “Evaluation of Potential Stat3-Regulated Genes in Human Breast Cancer”,Biochemical and Biophysical Research Communications335(2):292-299 (2005).
Iihan N. et al., “Functional Significance of Vascular Endothelial Growth Factor and its Receptor (Receptor-1) in Various Lung Cancer Types”,Clinical Biochemistry37(9):840-845 (2004).
Inan S. et al., “Immunolocalizations of VEGF, its Receptors Flt-1, KDR and TGF-β's in Epithelial Ovarian Tumors”,Histol Histopathol21(10):1055-1064 (2006).
Jacobs I.J. et al., “Progress and Challenges in Screening for Early Detection of Ovarian Cancer”,Molecular&Cellular Proteomics3(4):355-366 (2004).
Kodama J. et al., “Serum C-Reactive Protein as a Prognostic Factor in Patients with Epithelial Ovarian Cancer”,European Journal of Obstetrics&Gynecology and Reproductive Biology82(1):107-110 (1999).
Kumar H. et al., “Soluble FLT-1 is Detectable in the Sera of Colorectal and Breast Cancer Patients”,Anticancer Research22(3):1877-1880 (2002).
Le Page C. et al., “From Gene Profiling to Diagnostic Markers: IL-18 and FGF-2 Complement CA125 as Serum-Based Markers in Epithelial Ovarian Cancer”,Int. J. Cancer118(7):1750-1758 (2006).
Lokshin A.E. et al., “Circulating IL-8 and Anti-IL-8 Autoantibody in Patients with Ovarian Cancer”,Gynecologic Oncology102(2):244-251 (2006).
Macciò A. et al., “High Serum Levels of Soluble IL-2 Receptor, Cytokines, and C Reactive Protein Correlate with Impairment of T Cell Response in Patients with Advanced Epithelial Ovarian Cancer”,Gynecologic Oncology69(3):248-252 (1998).
Mathew R. et al., “Stromelysin-2 Overexpression in Human Esophageal Squamous Cell Carcinoma: Potential Clinical Implications”,Cancer Detection and Prevention26(3):222-228 (2002).
Matsumoto K. et al., “Prognostic Significance of Plasma Placental Growth Factor Levels in Renal Cell Cancer: An Association with Clinical Characteristics and Vascular Endothelial Growth Factor Levels”,Anticancer Research23(6D):4953-4958 (2003).
McCluggage W.G. et al., “Immunohistochemistry as a Diagnostic Aid in the Evaluation of Ovarian Tumors”,Seminars in Diagnostic Pathology22(1):3-32 (2005).
Meunier-Carpentier S. et al., “Comparison of the Prognosis Indication of VEGFR-1 and VEGFR-2 and Tie2 Receptor Expression in Breast Carcinoma”,International Journal of Oncology26(4):977-984 (2005).
Miyata Y. et al., “Expression of Matrix Metalloproteinase-10 in Renal Cell Carcinoma and its Prognostic Role”,European Urology52(3):791-797 (2007).
Mor G. et al., “Serum Protein Markers for Early Detection of Ovarian Cancer”,PNAS102(21):7677-7682 (2005).
Moradi M.M. et al,. “Serum and Ascitic Fluid Levels of Interleukin-1, Interleukin-6, and Tumor
Glezer Eli
Mathew Anu
Stengelin Martin
Aeder Sean
Meso Scale Technologies LLC
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Diagnostic methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288625